Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 76420-236

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 76420-236). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Asclemed Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

1 (Image 1)

1 (Image 1)
FDA Label Image

Figure9 (Image 10)

Figure9 (Image 10)
The text describes a graph that shows the percentage of patients who have shown improvement in pain after taking Duloxetine Delayed-Release 60 mg Once Daily. The graph also shows a comparison with a placebo. The X-axis shows the percentage of improvement in pain, while the Y-axis shows the percentage of patients who have shown improvement.*
FDA Label Image

Figure10 (Image 11)

Figure10 (Image 11)
The text is describing a chart showing the percentage of patients who improved with a placebo and Duloxetine Delayed-Release at different dosages. It also shows the percentage improvement in pain from baseline using BOCF.*
FDA Label Image

1 (Image 12)

1 (Image 12)
FDA Label Image

Label 30 mg (Image 13)

Label 30 mg (Image 13)
FDA Label Image

1 (Image 2)

1 (Image 2)
FDA Label Image

Figure1 (Image 3)

Figure1 (Image 3)
FDA Label Image

Figure2 (Image 4)

Figure2 (Image 4)
The text is a graph showing the proportion of patients with relapse over time for a medication (Duloxetine Delayed-Release Capsules) and a placebo. The x-axis represents the time from randomization to relapse (in days) and the y-axis represents the proportion of patients. The graph appears to use the Kaplan-Meier method to estimate the proportion of patients.*
FDA Label Image

Figure3 (Image 5)

Figure3 (Image 5)
FDA Label Image

Figure4 (Image 6)

Figure4 (Image 6)
FDA Label Image

Figure5 (Image 7)

Figure5 (Image 7)
FDA Label Image

Figure6 (Image 8)

Figure6 (Image 8)
FDA Label Image

Figure8 (Image 9)

Figure8 (Image 9)
The text describes a graph that shows the percentage of patients who improved with a placebo and Duloxetine Delayed-Release doses of 60/120 mg once daily. The percentage of improvement in pain from baseline is also shown on the graph.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.